# MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

> **NCT06541249** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 54 (estimated)

## Conditions studied

- Polycythemia Vera (PV)
- Essential Thrombocythemia (ET)
- Myelofibrosis (MF)

## Interventions

- **DRUG:** Methotrexate (MTX)

## Key facts

- **NCT ID:** NCT06541249
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-02
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06541249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06541249, "MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06541249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*